Treatment Modalities of Psoriasis: A Focus on Requisite for Topical Nanocarrier

被引:5
|
作者
Ramanunny, Arya K. [1 ]
Wadhwa, Sheetu [1 ]
Thakur, Divya [2 ]
Singh, Sachin K. [1 ]
Kumar, Rajesh [1 ]
机构
[1] Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, Punjab, India
[2] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala, Punjab, India
关键词
Skin; psoriasis; cytokines; nanocarriers; topical; route of administration; LOADED CHITIN NANOGEL; DIPROPIONATE AEROSOL FOAM; PLAQUE-TYPE PSORIASIS; BOX-BEHNKEN DESIGN; DOUBLE-BLIND; IN-VITRO; BETAMETHASONE DIPROPIONATE; CYCLOSPORINE-A; UVB PHOTOTHERAPY; SALICYLIC-ACID;
D O I
10.2174/1871530320666200604162258
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective: Psoriasis is an autoimmune skin disease involving cascading release of cytokines activated by the innate and acquired immune system. The increasing prevalence rate of psoriasis demands for more appropriate therapy. The existing chemical moiety is promising for better therapeutic outcome, but the selection of a proper channel for administration has to be reviewed. Hence there is a need to select the most appropriate dosage form and route of administration for improving the curative rate of psoriasis. Results: A total of 108 systematic reviews of research and review articles were conducted to make the manuscript comprehensible. The role of inflammatory mediators in the pathogenesis of the disease is discussed for a better understanding of the selection of pharmacotherapy. The older and newer therapeutic moiety with its mode of administration for psoriasis treatment has been discussed. With a comparative review on topical and oral administration of first-line drugs such as methotrexate (MTX), cyclosporine (CsA), and betamethasone, its benefits-liabilities in the selected routes were accounted for. Emphasis has also been paid on advanced nanocarriers for dermatologic applications. Conclusion: For a better therapeutic outcome, proper selection of drug moiety with its appropriate administration is the major requisite. With the advent of nanotechnology, the development of nanocarrier for dermatologic application has been successfully demonstrated in positioning the systemically administrated drug into topical targeted delivery. In a nutshell, to achieve successful treatment strategies towards psoriasis, there is a need to focus on the development of stable, non-toxic nanocarrier for topical delivery. Inclusion of the existing orally administered drug moiety into nanocarriers for topical delivery is proposed in order to enhance therapeutics payload with reduced side effects which serves as a better treatment approach for relief of the psoriasis condition.
引用
收藏
页码:418 / 433
页数:16
相关论文
共 50 条
  • [31] Emerging topical treatments for psoriasis
    Kivelevitch, Dario N.
    Hebeler, Katherine R.
    Patel, Mahir
    Menter, Alan
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (04) : 523 - 532
  • [32] New topical treatments for psoriasis
    Chiricozzi, Andrea
    Pitocco, Rossella
    Saraceno, Rosita
    Nistico, Steven Paul
    Giunta, Alessandro
    Chimenti, Sergio
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (04) : 461 - 470
  • [33] Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments
    Kleyn, Elise C.
    Morsman, Elaine
    Griffin, Lizelle
    Wu, Jashin J.
    van de Kerkhof, Peter C. M.
    Gulliver, Wayne
    van der Walt, Joelle M.
    Iversen, Lars
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 311 - 319
  • [34] Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation
    Purvis, Caitlin G.
    Balogh, Esther A.
    Heron, Courtney E.
    Feldman, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (09) : 1107 - 1117
  • [35] Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis
    Baboota, Sanjula
    Alam, Md Sarfaraz
    Sharma, Shrestha
    Sahni, Jasjeet K.
    Kumar, Anil
    Ali, Javed
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2011, 1 (03) : 139 - 147
  • [36] Topical Treatment Habits in Psoriasis Patients Receiving Adalimumab
    Kolios, A. G. A.
    Rusca, F.
    Reisenbauer, K.
    Cozzio, A.
    French, L. E.
    Navarini, A. A.
    DERMATOLOGY, 2012, 224 (03) : 228 - 230
  • [37] Scalp psoriasis: a review of current topical treatment options
    Papp, K.
    Berth-Jones, J.
    Kragballe, K.
    Wozel, G.
    De la Brassinne, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 (09) : 1151 - 1160
  • [38] Topical Botanical Agents for the Treatment of Psoriasis: A Systematic Review
    Farahnik, Benjamin
    Sharma, Divya
    Alban, Joseph
    Sivamani, Raja K.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (04) : 451 - 468
  • [39] Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs
    Martins, Ana M.
    Ascenso, Andreia
    Ribeiro, Helena Margarida
    Marto, Joana
    MOLECULAR NEUROBIOLOGY, 2020, 57 (05) : 2391 - 2419
  • [40] Treatment of Nail Psoriasis
    Hwang, Jonathan K.
    Lipner, Shari R.
    DERMATOLOGIC CLINICS, 2024, 42 (03) : 387 - 398